Biotech and pharma sales cycles run through scientific reviewers, procurement committees, and compliance sign-off before a deal closes. Most sales enablement content is written for a single decision-maker who does not exist in this market. We build the materials, objection playbooks, and scientific proof points that actually move a biotech deal forward.
The Problem
Deals get routed through scientific reviewers, not just buyers
A biotech or pharma sale rarely closes on a single champion's word. Technical evaluators, lab directors, or medical affairs staff sit in the approval chain and expect data, not adjectives. Reps armed with generic value-prop decks get stuck when a reviewer asks for the methodology behind a claim, and the deal stalls while someone scrambles to produce backup that should have existed from day one.
Compliance review turns every asset into a bottleneck
Marketing claims that would be routine in most B2B categories need legal and regulatory sign-off before a rep can use them in a pharma or biotech context. When enablement content is not built with that review cycle in mind, reps end up improvising in the room or falling back on outdated one-pagers because the current version is still sitting in review. The sales cycle inherits the compliance bottleneck by default.
Long, multi-stakeholder cycles erode momentum between touches
Biotech and pharma buying committees can span procurement, R&D, clinical, and finance, with weeks between meetings. Without a structured way to keep every stakeholder aligned on where the deal stands, reps re-explain the same value proposition to each new person in the chain instead of building on what was already agreed. Deals that should close in a quarter drift into two or three.
Reps default to generic pitches because nothing vertical-specific exists
Most sales enablement libraries are built once, for the broadest possible audience, then reused across every vertical the company sells into. A rep selling into a biotech account ends up pulling the same case study and objection handling used for a retail account, stripped of the scientific credibility and regulatory awareness that a biotech buyer expects to see in the first five minutes.
How We Help
We start by sitting in on live sales calls and reviewing lost-deal notes to find where biotech and pharma deals actually stall. In most cases it is not the pitch itself but the follow-up moment: a technical question the rep cannot answer cleanly, or a compliance-sensitive claim nobody has pre-cleared. That gap becomes the starting point for the enablement build, not a generic template refresh.
Strategy development maps the buying committee role by role. We identify what a lab director needs to see versus what a procurement lead needs to see, and build separate assets for each rather than one deck stretched to cover everyone. Objection handling gets built from real objections your reps have already heard, organized so a rep can find the right response in seconds during a live call.
Execution means building the actual materials: battlecards with pre-cleared scientific claims, ROI calculators using real inputs instead of hypothetical numbers, discovery question guides tuned to biotech and pharma buying signals, and a compliance-friendly review workflow so new claims do not sit in legal for three weeks. We work directly with your legal and regulatory team during the build so the final assets are already approved, not stuck waiting for sign-off after launch.
We also train the team on how to use the materials, not just hand them off. That means live role-play on the toughest scientific objections, a shared language for qualifying multi-stakeholder deals, and a simple way to track which assets are actually getting used versus ignored. Measurement closes the loop: we track win rate by deal stage, time-to-close, and which assets correlate with deals that actually move, then rebuild whatever is not working instead of leaving it in the library out of habit.
What we deliver
- Stakeholder-mapped battlecards – separate materials for scientific reviewers, procurement, and clinical or medical affairs, each with pre-cleared claims
- Objection playbook built from real lost-deal data – not hypothetical objections, the ones your reps have actually heard
- Compliance-cleared claim library with a fast review workflow so new assets do not stall in legal
- Discovery and qualification guide tuned to how biotech and pharma buying committees actually move through a deal
In biotech and pharma sales, the deal usually does not stall because the pitch was weak. It stalls because a scientific reviewer asked a question nobody prepared the rep to answer, and there was no pre-cleared answer sitting ready to go.
Our Methodology
Our 90-day sales enablement sprint opens with a diagnostic phase built on real call recordings, CRM stage data, and interviews with reps and sales leadership. We are looking for the specific moments deals stall, not building a generic content audit. This produces a prioritized list of the exact gaps costing the most deals, ranked by revenue impact rather than by what is easiest to fix first.
Days 30 to 60 build the core asset library: stakeholder-specific battlecards, the objection playbook, and the compliance-cleared claim set, all developed in parallel with your legal and regulatory reviewers so nothing launches half-approved. Days 60 to 90 shift to rollout and reinforcement – live training sessions, role-play on the hardest scientific objections, and a lightweight system for reps to flag new objections as they come up in the field.
What makes this different from a traditional sales enablement engagement is that we do not treat compliance as an afterthought bolted onto the content at the end. Regulatory and legal review happens during the build, which is the difference between a battlecard your reps can use the day it launches and one that sits in review for a month.
How We Work
The first 30 days run heavy – typically 3 days a week embedded with sales leadership, marketing, and legal to build the diagnostic and start drafting core assets. Days 30 to 90 taper to 1-2 days a week as we move into asset production, compliance review, and training rollout.
On your side, we need access to CRM data, recorded sales calls where available, and time with your legal or regulatory reviewer during the build phase – not just at the end. We handle the research, drafting, and training design. Your reps and sales leadership own the field execution and give us the feedback loop we need to keep refining the materials.
Weekly working sessions track asset production against the priority list from the diagnostic. Monthly reviews look at usage data and early deal-stage movement. Most engagements run 4-6 months for the initial build and rollout, with an optional retainer to keep the library current as products, competitors, and regulatory guidance shift.
- Shorter time-to-close on multi-stakeholder deals
- Higher rep confidence handling scientific and compliance objections
- Asset usage tied directly to deal-stage movement, not vanity download counts
If your biotech & pharma company needs sales enablement leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does sales enablement cost for a biotech or pharma company?
Engagements typically run $12K to $25K per month depending on how much of the asset library needs to be built from scratch versus refreshed. Companies with an existing but outdated library land at the lower end. Companies with no formal enablement function and a large multi-stakeholder deal cycle land higher because of the volume of stakeholder-specific assets needed. Most initial builds run 4-6 months.
How long before we see results from a sales enablement engagement?
Reps typically start using new objection handling and battlecards within the first 30-45 days as assets clear compliance and roll out. Measurable movement in win rate and time-to-close usually shows up by month 3, once enough deals have moved through the full cycle with the new materials. Full impact on cycle length takes a full sales cycle to confirm, which for biotech and pharma can run 4-9 months.
How does the sales enablement team integrate with our existing staff?
We work directly with your sales leadership, marketing, and legal or regulatory reviewers rather than operating in isolation. Your reps stay the ones in the room with buyers – our job is making sure they walk in with pre-cleared answers to the questions that actually stall deals. Weekly syncs keep the asset build aligned with what reps are hearing in live calls.
What makes Winston Francois different from a traditional sales enablement agency?
Most sales enablement vendors build generic templates and hand them off without touching compliance review, which means the materials sit unused while legal catches up. We build the compliance review into the process from day one, so assets launch already cleared. We also build from real lost-deal data instead of hypothetical objections, which is why the materials tend to actually get used.
How do you measure ROI from a sales enablement engagement?
We track win rate by deal stage, time-to-close, and which specific assets correlate with deals that progress versus stall. Asset usage data gets tied to CRM outcomes rather than reported as downloads or views. Most engagements need one full sales cycle, often a full quarter or two for biotech and pharma, before the ROI numbers are reliable.
What type of biotech or pharma company is the right fit for this service?
Companies at Series A through growth stage with an active commercial or business development team selling into a multi-stakeholder buying process – lab directors, procurement, clinical staff, or medical affairs. The best fit is a company with real deal flow but reps who are improvising materials on the fly, not a company still pre-revenue with no sales motion to enable yet.
